Qure.ai, a leading innovator in medical imaging AI, has recently been granted breakthrough device designation by the Food and Drug Administration's (FDA) Center for Devices and Radiological Health (CDRH) for its AI-powered Tuberculosis (TB) solution, known as qSpot-TB.
This significant recognition from regulatory authorities adds to Qure.ai's list of achievements, which includes four FDA clearances and 61 approvals under the European Union Medical Device Regulation (EU MDR) CE mark in the past eighteen months.
qSpot-TB utilizes artificial intelligence (AI) as a second-read computer-aided detection and diagnosis tool. It analyzes chest X-rays to identify all radiological signs suggestive of TB and provides a conclusive assessment of the presence or absence of the disease. This technology is particularly valuable for healthcare professionals, especially given the recent increase in TB cases in developed countries like the United States.
Bunty Kundnani, Chief Regulatory Affairs Officer at Qure.ai, emphasized the company's commitment to advancing AI medical innovation while adhering to strict regulatory standards across more than 85 countries. Kundnani highlighted the significance of achieving clearances from both the FDA and EU MDR for various imaging modalities and diseases, which enables Qure.ai to effectively support radiology teams in prioritizing patient cases and expediting decision-making processes.
The FDA's decision to grant breakthrough device designation to Qure's qSpot-TB device signifies a significant advancement in AI-assisted diagnosis for tuberculosis. TB remains a significant public health concern, not only in developing nations but also in Western societies such as the UK and USA, where TB rates have increased following the COVID-19 pandemic. The ongoing collaboration between Qure.ai and the FDA on the regulatory process for breakthrough devices reflects the importance of continuous innovation in TB detection and screening.
Professor Kenneth G. Castro, MD, from Emory University, emphasized the importance of global collaboration in combating TB, highlighting the role of innovative technology in accelerating progress toward the elimination of the disease.
Despite a long-term decline in TB cases in the United States, there has been a recent resurgence, with the Centers for Disease Control and Prevention reporting 8,300 cases in 2022. Similarly, in England, data from the UK Health Security Agency revealed a 7% increase in TB cases in the first half of 2023 compared to the same period in 2022.
These statistics underscore the ongoing need for collective efforts and technological advancements to combat TB effectively on a global scale.